Completion of acquisition of BioForLife Italia S.r.l.

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000 E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 October 1, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Symbol: VIYASH Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – Completion of acquisition of BioForLife Italia S.r.l Dear Sir/ Madam, Pursuant to Regulation 30 of the SEBI Listing Regulations, and in continuation of our earlier disclosures dated June 8, 2026, July 21, 2026, and September 8, 2026 (collectively referred to as the “Disclosures”) and pursuant to the receipt of necessary approvals, we wish to inform you that Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific Limited (“the Company”), has completed the acquisition of 100% of the share capital of BioForLife Italia S.r.l., Milan, Italy (“BFL Italy”), on October 1, 2026, pursuant to the terms of Sale and Purchase Agreement dated July 21, 2026, executed between BFL Italy and Alivira Animal Health Limited, Ireland (“SPA”). Consequently, BFL Italy has become a step-down wholly owned subsidiary of the Company with effect from October 1, 2026. The transaction has been completed in accordance with the terms of the SPA and the connected transaction documents. The base purchase consideration being paid on the closing is comprising of EUR 15.0 million and the agreed reference net financial position computed as of June 30, 2026 in terms of the SPA. The balance purchase consideration of EUR 1.976 million is payable as deferred consideration, subject to necessary adjustments basis the computation of net financial position as on Closing Date (i.e October 1, 2026), in accordance with the SPA. As part of closing under the SPA, the representatives of Alivira Animal Health Limited, Ireland have been appointed on the Board of BFL Italy. The Company completed the acquisition in accordance with the terms and conditions previously disclosed. Accordingly, the transaction stands consummated and closed. We request you to take the same on record. Yours faithfully, For Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer